Together these results suggested that doxorubicin causes nuclear relocation of FOXO3a in the drug sensitive breast cancer cells, and confirmed our previous data that FOXO3a expression is predominantly nuclear in the resistant cells. Here, FOXO3 is linked to breast cancer.